Straits Times Index
3,325.08 -1.20 (-0.04%) Nikkei
39,667.07 +493.92 (+1.26%) Hang Seng
18,089.93 +17.03 (+0.09%) FTSE 100
8,298.14 +50.35 (+0.61%) Bitcoin USD
61,508.49 +750.80 (+1.24%) CMC Crypto 200
1,279.29 -4.50 (-0.35%)
HALO Dec 2024 60.000 call
| Previous close | 1.8100 |
| Open | 1.8100 |
| Bid | 1.3000 |
| Ask | 4.5000 |
| Strike | 60.00 |
| Expiry date | 2024-12-20 |
| Day's range | 1.8100 - 1.8100 |
| Contract range | N/A |
| Volume | |
| Open interest | 62 |
PR NewswireHalozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Roche received European Commission (EC) marketing authorization of OCREVUS® (ocrelizumab) SC co-formulated with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme, rHuPH20, for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).
Simply Wall St.Halozyme Therapeutics (NASDAQ:HALO) shareholder returns have been stellar, earning 193% in 5 years
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
- PR Newswire
Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that argenx received U.S. Food and Drug Administration (FDA) approval for VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) co-formulated with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme, rHuPH20, for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP).
